[1] ZHOU ZG.Guidelines for diagnosis and treatment of type 1 diabetes in China[M]. Beijing:People’s Medical Publishing House(人民卫生出版社), 2012. [2] FU J, SHI BY.Fulminant type 1 diabetes: A distinct subtype of type 1 diabetes mellitus[J]. J Formos Med Assoc, 2013, 112(6): 363-364. [3] WANG O, PAN H, XIANG HD.A case of human insulin allergy[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2002, 10(5): 306-307. [4] CHAKRABORTY PP, BISWAS SN, PATRA S.Faulty injection technique: a preventable but often overlooked factor in insulin allergy[J]. Diabetes Ther, 2016, 7(1): 163-167. [5] JIN RC, HUANG J.Clinical characteristics and management of allergic reaction to insulin preparation[J]. Chinese Journal of Endocrinology and Metabolis(中华内分泌代谢杂志), 2013, 29(9): 1-4. [6] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848. [7] BECKER RH, FRICK AD.Clinical pharmacokinetics and pharmacodynamics of insulin glulisine[J]. Clin Pharmacokinet, 2008, 47(1): 7-20. [8] GARG SK, ELLIS SL, ULRICH H.Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes[J]. Expert Opin Pharmacother, 2005, 6(4): 643-651. [9] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848. [10] ZHAO WG.Selection of fast insulin analogues in insulin pump therapy based on guidelines[J]. Drug Evaluation(药品评价), 2020, 17(9):1-3, 29. [11] HOOGMA RP, SCHUMICKI D.Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes[J]. Horm Metab Res, 2006, 38(6): 429-433. [12] MUNIR KM, DAVIS SN.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus[J]. Expert Opin Pharmacother, 2015, 16(15): 2331-2341. [13] TATTERSALL R.Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes[J]. Diabet Med, 1993, 10(8): 688-693. [14] DIMITRIADIS GD, TESSARI P, GO VL, et al.alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus[J]. Metabolism, 1985, 34(3): 261-265. [15] YUKINA M, NURALIEVA N, SOLOVYEV M, et al.Insulin autoimmune syndrome[J]. Endocrinol Diabetes Metab Case Rep, 2020 Jun 4, 2020: 190159. [16] OAK S, PHAN TH, GILLIAM LK, et al.Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin[J]. Acta Diabetol, 2010, 47(2):131-135. [17] ISHIZUKA T, OGAWA S, MORI T, et al.Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies[J]. Diabetes Res Clin Pract, 2009, 84(2):e21-e23. [18] VAN HAEFTEN TW.Clinical significance of insulin antibodies in insulin-treated diabetic patients[J]. Diabetes Care, 1989, 12(9): 641-648. [19] IONESCU-TÎRGOVIŞTE C, MINCU I, SIMIONESCU L, et al. Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients[J]. Diabetologia, 1984, 27(6):592-595. [20] SHEN Y, SONG X, REN Y.Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series[J]. BMC Endocr Disord, 2019, 19(1): 148. [21] QUAN H, TAN H, LI Q, et al.Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes[J]. J Diabetes Res, 2015, 2015: 1-9. [22] BODE BW.Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine[J]. Endocr Pract, 2011, 17(2): 271-280. |